DiaMedica Therapeutics Inc. Operating Income Loss

• DiaMedica Therapeutics Inc. showed a decrease of -28.9% in Operating Income Loss from 2024 to 2025.
• This data is from DiaMedica Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), DiaMedica Therapeutics Inc.'s Operating Income Loss has declined by 661.2%.
• Historical annual values: Fiscal year 2025: -$34.40 million | Fiscal year 2024: -$26.68 million | Fiscal year 2023: -$21.27 million | Fiscal year 2022: -$14.00 million | Fiscal year 2021: -$13.65 million | Fiscal year 2020: -$12.70 million | Fiscal year 2019: -$11.59 million | Fiscal year 2018: -$6.76 million | Fiscal year 2017: -$4.52 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026